Clinical trials: Graves' Ophthalmopathy
Thyroid Eye Disease
Anti-VEGF Therapy for Acute Thyroid Eye Disease
The primary objective of this clinical trial is to assess the safety and tolerability of sub-tenon aflibercept in combination with either saline or hyaluronidase (HA) in patients with acute Thyroid Eye Disease (TED) as assessed…
- Trial name
- AcTED (NCT04311606)
- Testing
- Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Graves' Disease
Early Levothyroxine Post Radioactive Iodine
The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves'disease will prevent overt hypothyroidism (low thyroid hormone levels).
- Trial name
- NCT01950260
- Testing
- Levothyroxine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Mayo Clinic
Thyroid Eye Disease, Graves Orbitopathy
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD).
- Trial name
- ORBIT (NCT04737330)
- Testing
- Secukinumab
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Ophthalmopathy, Thyroid-Associated
Rituximab (RTX) Therapy in Patients With Active TAO
Thyroid Associated Ophthalmopathy is condition affecting the eyes of about 10% of patients with Graves disease. Its combination of protrusion affecting the looks of the patient and pain is often severely affecting the quality of…
- Trial name
- NCT02378298
- Testing
- Rituximab, Iv Methylprednisolone, peroral methylprednisolone and Methotrexate
- Where
- 5 sites in Sweden
- Volunteers
- 38 people
- Sponsor
- Göteborg University
Thyroid Eye Disease
Celecoxib for Thyroid Eye Disease
Thyroid eye disease (TED) is an autoimmune disorder in which the immune system attacks orbital tissues, resulting in characteristic changes in eyelid position, globe position in the orbit, extraocular muscle balance, and optic…
- Trial name
- NCT02845336
- Testing
- Celecoxib, artificial tears
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University
Thyroid Eye Disease, Graves Ophthalmopathy
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy
- Trial name
- NCT06226545
- Testing
- LASN01
- Where
- 15 sites in United States, Spain and 1 more
- Volunteers
- 41 people
- Sponsor
- Lassen Therapeutics Inc.
Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment…
- Trial name
- NCT01868997
- Testing
- teprotumumab, normal saline
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 88 people
- Sponsor
- Amgen
Thyroid-associated Ophthalmopathy
Trial of Rituximab for Graves' Ophthalmopathy
This study is being done to investigate the effects (good and bad) of Rituximab for the treatment of an autoimmune eye disease called Graves' ophthalmopathy. This disease has proven to be difficult to treat.
- Trial name
- NCT00595335
- Testing
- Rituximab, Saline, Methylprednisolone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rebecca Bahn
Graves' Disease
Radioactive Iodide Therapy for Pediatric Graves' Disease
The investigators hypothesize that 131I is an effective therapy for children with Graves' Disease (GD) and will not be associated with long-term cancer risks when used in older children, but may be associated with excessive…
- Trial name
- NCT01269749
- Testing
- RAI treatment, ATD Group
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Florida
Thyroid Eye Disease
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- OLE (NCT06179875)
- Testing
- Veligrotug
- Where
- 45 sites in United States, France and 6 more
- Volunteers
- 139 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
- Trial name
- THRIVE-2 (NCT06021054)
- Testing
- Veligrotug
- Where
- 57 sites in United States, Australia and 7 more
- Volunteers
- 188 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid Eye Disease
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of thyroid eye disease (TED) in participants who participated in the lead-in study HZNP-TEP-301 (NCT03298867; OPTIC) and who were…
- Trial name
- OPTIC-X (NCT03461211)
- Testing
- Teprotumumab
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Amgen